Xie Weijie, Li Yuan, Wang Xinyue, Blokhina Elena, Krupitsky Evgeny, Vetrova Marina, Hu Ji, Yuan Ti-Fei, Chen Jue, Wang Hua, Chen Xiangfang
Clinical Research Center for Mental Disorders, Shanghai Pudong New Area Mental Health Center Tongji University School of Medicine Shanghai China.
Shanghai Key Laboratory of Psychotic Disorders, Brain Health Institute, National Center for Mental Disorders, Shanghai Mental Health Center Shanghai Jiaotong University School of Medicine Shanghai China.
MedComm (2020). 2025 Apr 16;6(5):e70163. doi: 10.1002/mco2.70163. eCollection 2025 May.
Gamma-aminobutyric acid (GABA) B receptors (GABARs) that acts slowly and maintains the inhibitory tone are versatile regulators in the complex nervous behaviors and their involvement in various neuropsychiatric disorders, such as anxiety, epilepsy, pain, drug addiction, and Alzheimer's disease. Additional study advances have implied the crucial roles of GABARs in regulating feeding-related behaviors, yet their therapeutic potential in addressing the neuropsychiatric disorders, binge eating, and feeding-related disorders remains underutilized. This general review summarized the physiological structure and functions of GABAR, explored the regulation in various psychiatric disorders, feeding behaviors, binge eating, and metabolism disorders, and fully discussed the potential of targeting GABARs and its regulator-binding sites for the treatment of different psychiatric disorders, binge eating and even obesity. While agonists that directly bind to GABAR1 have some negative side effects, positive allosteric modulators (PAMs) that bind to GABAR2 demonstrate excellent therapeutic efficacy and tolerability and have better safety and therapeutic indexes. Moreover, phosphorylation sites of downstream GABARs regulators may be novel therapeutic targets for psychiatric disorders, binge eating, and obesity. Further studies, clinical trials in particular, will be essential for confirming the therapeutic value of PAMs and other agents targeting the GABAR pathways in a clinical setting.
γ-氨基丁酸(GABA)B受体(GABARs)作用缓慢并维持抑制性张力,是复杂神经行为中的多功能调节因子,且参与多种神经精神疾病,如焦虑症、癫痫、疼痛、药物成瘾和阿尔茨海默病。更多的研究进展表明GABARs在调节进食相关行为中起关键作用,但其在治疗神经精神疾病、暴饮暴食和进食相关疾病方面的治疗潜力仍未得到充分利用。这篇综述总结了GABAR的生理结构和功能,探讨了其在各种精神疾病、进食行为、暴饮暴食和代谢紊乱中的调节作用,并充分讨论了靶向GABARs及其调节剂结合位点治疗不同精神疾病、暴饮暴食甚至肥胖症的潜力。虽然直接与GABAR1结合的激动剂有一些负面副作用,但与GABAR2结合的正变构调节剂(PAMs)显示出优异的治疗效果和耐受性,且具有更好的安全性和治疗指数。此外,下游GABARs调节剂的磷酸化位点可能是治疗精神疾病、暴饮暴食和肥胖症的新靶点。进一步的研究,尤其是临床试验,对于在临床环境中确认PAMs和其他靶向GABAR途径的药物的治疗价值至关重要。